Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
RIDOGREL AS AN ADJUNCT TO THROMBOLYSIS IN ACUTE MYOCARDIAL-INFARCTION
Autore:
VANDERWIEKEN LR; SIMOONS ML; LAARMAN GJ; VANDENBRAND M; NIJSSEN KM; DELLBORG M; HERMENS W; VROLIK W;
Indirizzi:
ONZE LIEVE VROUW HOSP,DEPT CARDIOL,OOSTERPARKST 279 1000 HM AMSTERDAMNETHERLANDS ERASMUS UNIV ROTTERDAM,THORAXCTR 3000 DR ROTTERDAM NETHERLANDS UNIV HOSP DIJKZIGT 3015 GD ROTTERDAM NETHERLANDS GOTHENBURG UNIV,OSTRA HOSP,DEPT MED S-41685 GOTHENBURG SWEDEN RES INST CARDIOVASC DIS MAASTRICHT NETHERLANDS UNIV HOSP GASTHUISBERG,DIV CARDIOL B-3000 LOUVAIN BELGIUM
Titolo Testata:
International journal of cardiology
fascicolo: 2, volume: 52, anno: 1995,
pagine: 125 - 134
SICI:
0167-5273(1995)52:2<125:RAAATT>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
TISSUE PLASMINOGEN-ACTIVATOR; THROMBOXANE-A2 SYNTHETASE INHIBITION; DYNAMIC QRS-COMPLEX; CORONARY THROMBOLYSIS; PLATELET-AGGREGATION; SYNTHASE INHIBITION; ONE MOLECULE; RT-PA; THERAPY; PATENCY;
Keywords:
MYOCARDIAL INFARCTION; THROMBOLYSIS; RIDOGREL; THROMBOXANE SYNTHETASE INHIBITOR; THROMBOXANE RECEPTOR BLOCKER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
39
Recensione:
Indirizzi per estratti:
Citazione:
L.R. Vanderwieken et al., "RIDOGREL AS AN ADJUNCT TO THROMBOLYSIS IN ACUTE MYOCARDIAL-INFARCTION", International journal of cardiology, 52(2), 1995, pp. 125-134

Abstract

An open pilot study was performed to assess the safety and preliminary efficacy of ridogrel, a selective thromboxane-A(2) synthetase inhibitor and thromboxane-A(2)/prostaglandin endoperoxide receptor blocker, as adjunct to thrombolysis with alteplase and heparin. In 50 patients with acute myocardial infarction, 300 mg ridogrel was injected intravenously in addition to alteplase and heparin. Ridogrel was continued orally (300 mg) twice daily for 5 days. Patency rate at initial (90 min)angiography, defined as thrombolysis in myocardial infarction perfusion grades 2 or 3, was 86%. Rescue percutaneous transluminal coronary angioplasty was performed in 10 patients; immediate results were good in nine, while a large dissection occurred in one patient. New ischemiaoccurred in 10 patients within 24 h, and after the second angiogram in seven cases. Three underwent coronary artery bypass grafting and seven percutaneous transluminal coronary angioplasty without further complication. Patency rate at second angiography (between 6 and 24 h) was 94%, New Q-waves appeared in 56% of the patients; 36% had a non-Q-waveinfarction and 8% had no enzyme rise, Enzymatic infarct size, estimated by the cumulative quantity of alpha-hydroxybutyrate dehydrogenase released in 72 h, was substantially smaller than in comparable studies with rt-PA and heparin. One patient died due to a cerebrovascular hemorrhage, No other deaths occurred. Bleeding complications were seen in 18 patients (36%), necessitating blood transfusion in three. Reinfarction did not occur. Eventually 49 patients were discharged in good condition, Safety with regard to bleeding complications of ridogrel in conjunction with alteplase is about the same as that of aspirin, Immediate and late patency rates were high. Rescue percutaneous transluminal coronary angioplasty could be performed with relative safety and early reocclusion could be successfully dealt with by repeat percutaneous transluminal coronary angioplasty. Further studies with this or similar compounds seem warranted.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/07/20 alle ore 08:04:47